• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 164

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Q3’25 Investor Survey: What are Investors Most Concerned About?

A European Model: Robert Schoevers on the Continent’s Growing Psychedelic Research Agenda

Psychedelic Insights Playground

GH Research Reports First Quarter 2022 Financial Results and Provides Business...

COMPASS Pathways presents largest ever study of psilocybin therapy, at American...

Incannex announces positive results from phase 2 clinical trial investigating the...

PT330 – Dick Simon – Researching Ethnobotanical Efficacy and the Search...

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 2

PT329 – Dr. Scott Shannon – The Board of Psychedelic Medicine...

Psychedelic Bulletin #107 – Call for Proposals: Opinions Column; How to...

PT328 – Courtney Watson, LMFT – Ancestral Veneration and Psychedelic-Assisted Therapy...

Exploring Ketamine’s Antimicrobial Effects & Fungal Sources: Part 1

PT327 – Rick Doblin, Ph.D. – Confronting Abuse in Clinical Trials...

1...163164165...300Page 164 of 300

EDITOR PICKS

The Psychedelic News Feed: October 20 – 26, 2025

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores...

Q3’25 Investor Survey: What are Investors Most Concerned About?

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©